Late-stage AML Emphasize Moleculin's lead candidate annamycin in late-stage development for relapsed/refractory AML, highlighting potential collaboration or licensing opportunities around MIRACLE trial data and cardiac safety profile to attract partners seeking effective AML therapies.

Cardiac Safety Edge Position annamycin's reduced cardiotoxicity as a differentiator in anthracycline therapies, targeting pharma backbones, academic consortia, and biopharma seeking safer standard-of-care options for resistant tumors.

Broad Antimetabolites Explore cross-industry partnerships around WP1122 and WP1066 for cancer and viral indications, presenting opportunities in oncology, infectious disease, and brain tumor programs to expand Moleculin's portfolio via co-development or licensing deals.

Viral & Cancer Synergy Leverage WP1122's potential COVID-19 and other viruses alongside oncologic applications to pursue multi-indication collaborations, grant programs, and international partnerships that boost portfolio diversification and market reach.

Investor & Market Momentum Capitalize on active conference and abstract activity, using upcoming ASCO, EHA, and investor event appearances to secure partnership discussions, funding rounds, and preclinical-to-clinical advancement partnerships aligned with Phase 2/3 timelines.